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ABSTRACT
Introduction: In the prospective, open-label
multicenter INTENSIFY study, the effectiveness
and tolerability of ivabradine as well as its
impact on quality of life (QOL) in chronic
systolic heart failure (CHF) patients were
evaluated over a 4-month period.
Methods: In CHF patients with an indication
for treatment with ivabradine, resting heart rate
(HR), heart failure symptoms [New York Heart
Association (NYHA) class, signs of
decompensation], left ventricular ejection
fraction, brain natriuretic peptide (BNP)
values, QOL, and concomitant medication
with focus on beta-blocker therapy were
documented at baseline, after 4 weeks, and
after 4 months. The results were analyzed
using descriptive statistical methods.
Results: Thousand nine hundred and fifty-six
patients with CHF were included. Their mean
age was 67 ± 11.7 years and 56.9% were male.
77.8% were receiving beta-blockers. Other
concomitant medications included
angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers (83%), diuretics
(61%), aldosterone antagonists (18%), and
cardiac glycosides (8%). At baseline, the mean
HR of patients was 85 ± 11.8 bpm, 51.1% and
37.2% of patients were classified as NYHA II and
III, respectively, and 22.7% showed signs of
decompensation. BNP concentrations were
tracked in a subgroup, and values exceeding
400 pg/mL were noted in 53.9% of patients. The
mean value of the European quality of life-5
dimensions (EQ-5D) QOL index was
0.64 ± 0.28. After 4 months of treatment with
ivabradine, HR was reduced to 67 ± 8.9 bpm.
Furthermore, the proportion of patients
presenting with signs of decompensation
decreased to 5.4% and the proportion of
patients with BNP levels[400 pg/mL dropped
to 26.7%, accompanied by a shift in NYHA
Trial registration: Controlled-trials.com, number
ISRCTN12600624.
Electronic supplementary material The online
version of this article (doi:10.1007/s12325-014-0147-3)
contains supplementary material, which is available to
authorized users.
C. Zugck (&)
Clinic/Group Practice for Internal Medicine, Steiner
Thor, Straubing, Germany
e-mail: zugck@gmx.net
P. Martinka  G. Sto¨ckl
Department of Medical Affairs, Servier Deutschland
GmbH, Munich, Germany
Adv Ther (2014) 31:961–974
DOI 10.1007/s12325-014-0147-3
classification towards lower grading (24.0% and
60.5% in NYHA I and II, respectively). EQ-5D
index improved to 0.79 ± 0.21.
Conclusion: Over 4 months of treatment,
ivabradine effectively reduced HR and
symptoms in CHF patients in this study
reflecting daily clinical practice. These benefits
were accompanied by improved QOL and good
general tolerability.
Keywords: Cardiology; Chronic heart failure;
Heart rate; Ivabradine; NYHA class; Quality of
life; Symptom reduction
INTRODUCTION
Elevated resting heart rate (HR) increases the
morbidity and mortality of patients with
chronic systolic heart failure (CHF) [1, 2] or
coronary artery disease with left ventricular
systolic dysfunction [3]. Furthermore, there is
substantial evidence that reduction in elevated
HR improves the outcome of patients with
cardiovascular diseases [4, 5]. Beta-blockers are
the primary pharmacological option available
to lower HR. They reduce left ventricular load,
suppress the adrenergic stimulus, improve
myocardial remodeling, and thereby reduce
cardiovascular morbidity and mortality [6].
Therefore, beta-blocking agents have been
recommended for many years in international
guidelines as a standard therapy in CHF [7].
However, many patients on beta-blocker
therapy, even if optimized, still present with
elevated HR [8, 9]. Other patients have
contraindications or cannot be treated with
beta-blockers due to intolerable side effects. For
several years, ivabradine has been available as
an alternative HR-reducing agent. It reduces HR
by selectively blocking the ‘‘funny’’ cardiac
pacemaker current (If) channel in the
pacemaker cells in the sinoatrial node. In
patients with chronic stable angina pectoris,
ivabradine has an anti-ischemic and anti-
anginal effect comparable to that of beta-
blockers [10] and calcium channel blockers [11].
Furthermore, the SHIFT study (Systolic Heart
faIlure treatment with the If inhibitor
ivabradine Trial; #ISRCTN70429960)
demonstrated that ivabradine also improved
the cardiovascular outcome of CHF patients
with an elevated HR (C70 bpm) compared with
placebo [12]. The risk for the composite primary
end point (cardiovascular death and hospital
admission for worsening heart failure) was
significantly reduced by 18%. Interestingly,
this risk reduction was achieved on top of
background pharmacotherapy, including beta-
blockers, recommended by heart failure
guidelines. A sub-analysis of SHIFT found that
patients with an initial HR C75 bpm gained a
significant benefit from ivabradine compared
with placebo in all pre-specified end points,
including risk of total mortality, CHF-associated
mortality, and hospital admission due to
worsening heart failure [13].
Consequently, the European Medicines
Agency approved ivabradine for CHF patients
in New York Heart Association (NYHA) classes
II to IV with reduced left ventricular ejection
fraction (LVEF) and a resting HR C75 bpm, also
in combination with beta-blocker therapy.
According to very recent registry data, the
prescription rates for ivabradine in patients
with reduced LVEF in Europe are still low,
while angiotensin-converting enzyme (ACE)
inhibitors/angiotensin receptor blockers
(ARBs) and beta-blockers are widely used [9].
Thus, data analyzing the use of ivabradine in
daily practice are still limited. Therefore, we
conducted a prospective, non-interventional,
open-label, multicenter study (INTENSIFY;
PractIcal daily effectiveNess and TolEraNce of
ivabradine in chronic SystolIc heart Failure in
962 Adv Ther (2014) 31:961–974
GermanY) to collect data on the use and
tolerability of ivabradine in an ambulatory
setting in patients suffering from CHF treated
by cardiologists, specialized general
practitioners (GPs), and internists. We focused
on the effect of ivabradine on HR reduction,
heart failure symptoms, and quality of life
(QOL).
METHODS
Patients with chronic systolic heart failure
fulfilling criteria for treatment with ivabradine
according to the approved indication or
European guideline [7] recommendations
(sinus rhythm, NYHA class II–IV, resting
HR C70/75 bpm) were included in the study
by treating physicians in an outpatient setting
(cardiologists, specialized GPs, and internists).
There were 3 scheduled visits, one at baseline
(visit 1), a control visit after 4 weeks (visit 2),
and the final examination after 4 months (visit
3). A standardized case report form was used to
record all data.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in 2000
and 2008. Informed consent was obtained from
all patients for being included in the study,
which was approved by the independent ethics
commission in Freiburg/Germany (FEKI). The
trial was registered at Controlled-trials.com,
number ISRCTN12600624.
After obtaining informed consent,
demographic and disease-specific medical
history data, as well as information about
concomitant diseases and the reason for
initiating ivabradine treatment, were
documented at visit 1. Patients were then
treated with ivabradine in flexible doses over a
4-month period. The recommended starting
dose was 5 mg twice daily (2.5 mg twice daily
for patients C75 years of age). If necessary, the
dose could be adjusted to 7.5 mg twice daily at
visit 2.
Heart failure was clinically documented at
each visit by recording HR, symptoms, signs of
decompensation (meaning ambulatory signs of
congestion like peripheral edema, worsening
dyspnea, developing ascites, etc.), LVEF,
concomitant medications, and QOL using the
validated European quality of life-5 dimensions
(EQ-5D) patient questionnaire.
To assess the overall response rate of patients
to ivabradine, treatment response was defined
as achieving an HR\70 bpm or an absolute
reduction of at least 10 bpm at visit 3, reflecting
the recommendations of the current European
Society of Cardiology (ESC) heart failure
guidelines [7] for treatment with ivabradine
and also the inclusion criteria of the SHIFT trial
(C70 bpm) [12].
Regarding analysis of concomitant
medication, the focus was beta-blocker therapy
with defined target doses of metoprolol 190 mg/
day, carvedilol 100 mg/day, as well as bisoprolol
and nebivolol 10 mg/day. For assessment of beta-
blocker treatment status of the cohort, patients
were divided into three subgroups according to
beta-blocker dose at baseline as a percentage
(\50%, 50–99%, C100%) of defined target doses.
Another three subgroups were specified
according to HR at baseline before ivabradine
treatment (\75 bpm, 75–84 bpm, C85 bpm). In
another subgroup of patients, levels of brain
natriuretic peptide (BNP) were available for each
visit. All occurring adverse events (AEs) during
the study period had to be documented and
assessed by the physician on a specific adverse
event reporting form at each patient visit (month
1 and month 4).
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Because of the non-interventional design of
the study, without a pre-defined statistical null
hypothesis, a purely descriptive statistical
analysis of the results was performed. Data are
presented as mean ± SD for continuous
variables and numbers of patients and/or
percentages for categorical variables. Baseline
and efficacy analysis included all patients with
complete age and sex data (full analysis set), and
all patients with any documentation were
included in the safety and tolerability analysis
(safety set). Data were analyzed statistically by
an independent statistical institute
(Metronomia Clinical Research GmbH,
Munich, Germany).
All statistical analyses have been performed
by means of the SAS software system (version
9.3 for Microsoft Windows; SAS Institute Inc.,
Cary, NC, USA).
RESULTS
In total, 1,956 patients with CHF were
documented by 694 centers in Germany. The
mean study duration was 126 ± 24.4 days. The
mean age of the cohort was 67 ± 11.7 years, and
56.9% of the patients were male.
The CHF diagnosis had been known for more
than 6 months in 85.4% of the population and
for more than 3 months in 14.6%. The etiology
of CHF was ischemic in 62.4% of patients, non-
ischemic in 31.7%, and both in 5.8%. Nearly all
patients (97.9%) presented with at least one
concomitant disease, most commonly
hypertension (85.1%), hyperlipidemia (60.3%),
diabetes mellitus (38.0%), and asthma/chronic
obstructive pulmonary disease (27.0%; Table 1).
As concomitant medication, 77.8% of
patients received beta-blockers (32.7%
metoprolol, 27.7% bisoprolol, 8.5% nebivolol,
and 6.6% carvedilol). 19.9% of patients received
at least the beta-blocker target dose, 55.8% at
least 50% but less than 100% of the target dose,
and 24.3% less than 50% of target dose
(Table 2). The mean daily dose was 103.7 mg
for metoprolol, 6.2 mg for bisoprolol, 5.4 mg for
nebivolol, and 27.7 mg for carvedilol (Table 3).
Apart from lower mean metoprolol dose in
the low HR group, there were no relevant
differences in average doses of beta-blockers
between patients with low (\75 bpm),
moderately elevated (75–84 bpm) and high
baseline HR (C85 bpm). The proportion of
patients receiving less than 50% of the beta-
blocker target dose was higher and the
proportion receiving 50–99% lower in the
subgroup with low HR, compared to the
subgroups with moderately elevated and high
HR (Table 3). Other concomitant medications
included ACE inhibitors or ARBs (83%),
diuretics (61%), aldosterone antagonists (18%),
cardiac glycosides (8%), aspirin (58%), and
statins (56%).
Insufficient HR lowering with a beta-blocker
was the most common reason for prescribing
ivabradine, documented in 74.6% of patients,
followed by decreased exercise capacity in
43.6% and intolerance to high doses of beta-
blockers in 40.5%. 90.4% of patients started
with 5 mg, 9.3% with 2.5 mg, and 0.2% with
7.5 mg twice daily. At visit 3, 44.1% of patients
received 5 mg, 52.4% were treated with 7.5 mg,
and 3.5% with 2.5 mg ivabradine twice daily.
The mean duration of treatment with
ivabradine was 123.4 ± 28.1 days. In 4.4% of
patients, the study drug was discontinued for
different reasons (50.0% patient’s request,
14.1% insufficient efficacy, 20.5% intolerance,
15.4% lack of compliance, and 29.5% other
reasons).
The mean HR of patients was reduced by
ivabradine from 85 ± 11.8 bpm at baseline to
72 ± 9.9 bpm after 1 month and 67 ± 8.9 bpm
after 4 months at visit 3 (Fig. 1). Relative HR
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Table 1 Baseline characteristics
Characteristics Male Female Total
n5 1,104 (56.9%) n5 837 (43.1%) n5 1,941 (100%)
Mean age 66 ± 11.2 68 ± 12.3 67 ± 11.7
\65 years 470 (42.6%) 280 (33.5%) 750 (38.6%)
65–80 years 538 (48.7%) 429 (51.3%) 967 (49.8%)
[80 years 96 (8.7%) 128 (15.3%) 224 (11.5%)
BMI, kg/m2 29 ± 4.6 28 ± 5.3 29 ± 4.9
Disease duration 1,031 (100.0%) 769 (100.0%) 1,800 (100.0%)
[3 months 161 (15.6%) 102 (13.3%) 263 (14.6%)
[6 months 870 (84.4%) 667 (86.7%) 1,537 (85.4%)
Disease etiology 1,094 (100.0%) 825 (100.0%) 1,919 (100.0%)
Ischemic 740 (67.6%) 458 (55.5%) 1,198 (62.4%)
Non-ischemic 281 (25.7%) 328 (39.8%) 609 (31.7%)
Both 73 (6.7%) 39 (4.7%) 112 (5.8%)
LVEF 982 (100.0%) 722 (100.0%) 1,704 (100.0%)
B35% 282 (28.7%) 171 (23.7%) 453 (26.6%)
[35% 700 (71.3%) 551 (76.3%) 1,251 (73.4%)
Signs of decompensation 1,087 (100.0%) 830 (100.0%) 1,917 (100.0%)
No 848 (78.0%) 633 (76.3%) 1,481 (77.3%)
Yes 239 (22.0%) 197 (23.7%) 436 (22.7%)
BNP 214 (100.0%) 146 (100%) 360 (100.0%)
B400 pg/mL 99 (46.3%) 67 (45.9%) 166 (46.1%)
[400 pg/mL 115 (53.7%) 79 (54.1%) 194 (53.9%)
NYHA class 1,094 (100.0%) 827 (100.0%) 1,921 (100.0%)
I 97 (8.9%) 87 (10.5%) 184 (9.6%)
II 576 (52.7%) 405 (49.0%) 981 (51.1%)
III 400 (36.6%) 315 (38.1%) 715 (37.2%)
IV 21 (1.9%) 20 (2.4%) 41 (2.1%)
Heart rate, bpm (n = 1,929) 85 ± 11.7 86 ± 11.9 85 ± 11.8
ECG
Sinus rhythm 922 (83.5%) 695 (83.0%) 1,617 (83.3%)
Atrial ﬁbrillation 104 (9.4%) 89 (10.6%) 193 (9.9%)
AV block 70 (6.3%) 32 (3.8%) 102 (5.3%)
Pacemaker 79 (7.2%) 25 (3.0%) 104 (5.4%)
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reduction was greater in patients with higher
baseline HR. Following the pre-specified
response definition of achieving an
HR\70 bpm or an absolute reduction of at
least 10 bpm at visit 3, 89.0% of all patients
had responded to treatment with ivabradine.
At baseline, NYHA grade I was recorded for
9.6% of patients, NYHA grade II for 51.1%,
NYHA grade III for 37.2%, and NYHA grade IV
for 2.1%. During the study, the proportion of
patients with NYHA III or IV decreased, whereas
the proportion of patients with NYHA I and II
increased. At visit 3, 24.0% of patients were
classified as NYHA I, 60.5% as NYHA II, 14.8%
as NYHA III, and 0.7% as NYHA IV (Fig. 2). The
change in NYHA class was comparable in all
three subgroups defined by baseline HR.
At baseline, 26.6% of patients had an
LVEF B35%. This proportion declined during
the study to 17.4% at visit 3 (Fig. 3). There were
no relevant differences either in baseline LVEF
or in LVEF changes between subgroups defined
by baseline HR.
At the initial visit, 22.7% of all patients
showed signs of decompensation (edema,
dyspnea, etc.). This proportion had decreased
to 5.4% at the final visit (Fig. 3). The proportion
of patients with signs of decompensation was
slightly lower at all three visits in the subgroup
with a baseline HR of\75 bpm compared with
Table 1 continued
Characteristics Male Female Total
n5 1,104 (56.9%) n5 837 (43.1%) n5 1,941 (100%)
ICD 60 (5.4%) 10 (1.2%) 70 (3.6%)
CRT 14 (1.3%) 8 (1.0%) 22 (1.1%)
Concomitant disease
Any 1,080 (97.8%) 821 (98.1%) 1,901 (97.9%)
Hypertension 932 (84.4%) 719 (85.9%) 1,651 (85.1%)
Diabetes 419 (38.0%) 319 (38.1%) 738 (38.0%)
Dyslipidemia 707 (64.0%) 463 (55.3%) 1,170 (60.3%)
Smoking 286 (25.9%) 102 (12.2%) 388 (20.0%)
Asthma 60 (5.4%) 90 (10.8%) 150 (7.7%)
COPD 246 (22.3%) 129 (15.4%) 375 (19.3%)
Depression 133 (12.0%) 164 (19.6%) 297 (15.3%)
Apoplex/TIA 67 (6.1%) 43 (5.1%) 110 (5.7%)
Hepatic disease 33 (3.0%) 14 (1.7%) 47 (2.4%)
Renal insufﬁciency 122 (11.1%) 93 (11.1%) 215 (11.1%)
Malignancy 31 (2.8%) 23 (2.7%) 54 (2.8%)
Sleep apnea 77 (7.0%) 30 (3.6%) 107 (5.5%)
AV atrioventricular, BMI body mass index, BNP brain natriuretic peptide, bpm beats per minute, COPD chronic obstructive
pulmonary disease, CRT cardiac resynchronization therapy, ECG electrocardiography, ICD implantable cardioverter
deﬁbrillator, LVEF left ventricular ejection fraction, NYHA New York Heart Association, TIA transient ischemic attack
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the two other subgroups with higher baseline
HRs. BNP concentration was tracked in 360
patients and exceeded 400 pg/mL in 53.9% at
baseline, and in 26.7% at visit 3 (Fig. 4).
Reductions in signs of decompensation and
BNP values were observed in all baseline HR
subgroups at the end of the study period. The
mean value of the QOL EQ-5D sum score index
was 0.64 ± 0.28 at baseline and had improved to
0.79 ± 0.21 at visit 3. A similar improvement was
seen in the EQ-5D visual analog scale (Fig. 5),
with comparable results in all HR subgroups.
Table 2 Beta-blocker therapy at baseline
Beta-blocker treatment/dosing Male (n5 1,104) Female (n5 837) Total (n5 1,941)
Any beta-blocker 893 (80.9%) 617 (73.7%) 1,510 (77.8%)
Metoprolol 387 (35.1%) 248 (29.6%) 635 (32.7%)
Bisoprolol 307 (27.8%) 231 (27.6%) 538 (27.7%)
Nebivolol 101 (9.1%) 64 (7.6%) 165 (8.5%)
Carvedilol 76 (6.9%) 52 (6.2%) 128 (6.6%)
Other 48 (4.3%) 37 (4.4%) 85 (4.4%)
% of target dosea 768 (100.0%) 535 (100.0%) 1,303 (100.0%)
\50% 173 (22.5%) 144 (26.9%) 317 (24.3%)
50–99% 434 (56.5%) 293 (54.8%) 727 (55.8%)
C100% 161 (21.0%) 98 (18.3%) 259 (19.9%)
a Deﬁned target doses of beta-blockers: metoprolol 190 mg/day, bisoprolol and nebivolol 10 mg/day, carvedilol 100 mg/day
Table 3 Beta-blocker mean daily doses in relation to target doses and heart rate at baseline
Beta-blocker dosing <75 bpm (n5 297) 75–84 bpm (n5 643) ‡85 bpm (n5 989) Total (n5 1,941)b
Mean dose (mg/day) (n = 1,345)
Metoprolol 95.8 ± 49.32 105.2 ± 46.20 104.4 ± 53.48 103.7 ± 50.67
Bisoprolol 6.9 ± 3.32 6.1 ± 2.64 6.1 ± 2.65 6.2 ± 2.77
Nebivolol 5.3 ± 2.21 5.4 ± 1.75 5.5 ± 2.14 5.4 ± 1.98
Carvedilol 29.5 ± 19.79 29.5 ± 19.79 27.6 ± 16.02 27.7 ± 17.04
% of target dosea 177 (100.0%) 459 (100.0%) 658 (100.0%) 1,303 (100.0%)
\50% 55 (31.1%) 101 (22.0%) 160 (24.3%) 317 (24.3%)
50–99% 82 (46.3%) 271 (59.0%) 367 (55.8%) 727 (55.8%)
C100% 40 (22.6%) 87 (19.0%) 131 (19.9%) 259 (19.9%)
bpm beats per minute
a Deﬁned target doses of beta-blockers: metoprolol 190 mg/day, bisoprolol and nebivolol 10 mg/day, carvedilol 100 mg/day
b No statistical imputation of missing values was performed. Patients with missing values for heart rate are included in the
‘‘total’’ column in case of existing documentation of beta-blocker dosing, though they are not considered in the stratiﬁed
heart rate analysis
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Overall, 2.9% of patients treated with
ivabradine reported at least one adverse event.
0.3% of patients died during the 4-month
follow-up period, reflecting a low-risk CHF
outpatient cohort. The most common adverse
events were cardiac (1.4%), related to the
nervous system (0.5%), or to the eye (0.5%).
Bradycardia was detected in 0.3% of patients
(n = 5) in the whole study cohort and was more
common in the group with baseline
HR\75 bpm than in the two subgroups with
higher baseline HRs (1.0% vs. 0% and 0.2%,
respectively).
In the final examination, the physicians
rated the effectiveness of ivabradine as very
good in 54.9% of patients and good in 41.5%.
The proportion of patients for whom
effectiveness was rated as very good was
higher in the subgroup with a baseline HR
of[85 bpm than in the 2 subgroups with lower
HR (58.4% vs. 51.5% and 50.2%, respectively).
Tolerability was rated by the physicians as very
good in 68.2% and good in 31% of patients. The
proportion of patients with tolerability rated as
very good was lower in the subgroup with
baseline HR\75 bpm than in the other
subgroups with higher baseline HRs (61.7% vs.
69.1% and 69.4%, respectively).
Detailed evaluation of other pre-defined
subgroups showed comparable effectiveness
(NYHA classification, signs of
decompensation), improvement in QOL, and
tolerability, independently of beta-blocker
dose (\50%, 50–99%, C100% of target dose),
LVEF (B35%,[35%), or age (\65 years,
65–80 years,[80 years), at baseline (subgroup
data not shown).
DISCUSSION
Treatment with ivabradine reduced resting HR
by 13 ± 10.3 bpm after 1 month (18 ± 12.3 bpm
after 4 months). The magnitude of this
reduction is similar to that observed in the
primary analysis of the SHIFT study [12]. The
baseline HR in that trial fell by 15.4 bpm from
79.9 bpm within 28 days. The placebo-corrected
difference was 10.9 bpm after 28 days, 9.1 bpm
after 1 year, and 8.1 bpm at the end of the study
after a median follow-up duration of
23 months. Due to the non-interventional
design no placebo group was included in
INTENSIFY, so placebo correction of HR
reduction was not possible. In SHIFT, an
uncorrected HR reduction (15 bpm) of the
same magnitude as achieved in INTENSIFY
Fig. 1 Mean resting heart rate during treatment with
ivabradine from baseline to study end (month 4). Data
presented as mean ± standard deviation. bpm beats per
minute
Fig. 2 Proportion of patients in different NYHA classes
from baseline to study end (month 4). NYHA New York
Heart Association
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(13 bpm) after 1 month resulted in a significant
improvement in patient outcome at the end of
follow-up [13].
Not only HR, but also functional class
improved. The proportion of patients classified
as NYHA I and II increased from 60.7 to 84.5%
in 4 months. A positive effect of selective HR
reduction on NYHA class is also supported by
the SHIFT study, with improvement in NYHA
class documented in 28% of patients on
ivabradine treatment [12].
The changes in NYHA class reported for the
patients in INTENSIFY represent a considerable
stabilization of CHF in a short period of time.
This is also reflected by an improvement of other
clinical parameters after 4 months: the
proportion of patients with an LVEF B35%
decreased from 26.6 to 17.4%, of patients with
signs of decompensation declined from 22.7
to 5.4%, and of patients with a BNP
level C400 ng/mL decreased from 53.9 to 26.7%.
The stabilizing effect on CHF induced by
ivabradine through reduction of HR is
supported by a study recently published by
Sargento et al. [14], showing that a significant
Fig. 4 Proportion of patients with BNP levels B400
or[400 pg/mL from baseline to study end (month 4).
BNP brain natriuretic peptide
Fig. 5 Quality of life of patients from baseline to study
end (month 4), evaluated by EQ-5D sum score index and
visual analog scale. Data presented as mean ± standard
deviation. EQ-5D European quality of life-5 dimensions
Fig. 3 Proportion of patients with LVEF B35% or[35% and with/without signs of decompensation from baseline to
study end (month 4). LVEF left ventricular ejection fraction
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44.5% decrease in N-terminal pro-BNP versus
baseline and improvement in NYHA class
achieved with 3-month ivabradine treatment
in ambulatory CHF patients on optimized
standard therapy closely correlated with the
degree of HR reduction and baseline HR. The
reduction in symptoms seen in INTENSIFY is
also in line with the data of Volterrani et al. [15]
demonstrating greater effects on exercise
capacity and NYHA status in CHF patients
(NYHA II–III) for ivabradine/carvedilol
combination therapy or ivabradine
monotherapy compared with carvedilol
monotherapy during a 3-month study period.
Also, QOL of patients was significantly
improved with ivabradine and combination
treatment versus baseline, while no effect was
shown for carvedilol monotherapy.
The hidden symptomatic ‘‘benefit reserve’’ in
the INTENSIFY cohort before the start of
ivabradine treatment could obviously not be
targeted solely with beta-blockers, which most
patients received. As CHF diagnosis was known
for more than 6 months in 85.4% of patients, it
is justified to consider that beta-blocker up-
titration has been completed in that period of
time. It should be noted that there was no
intensification of beta-blocker treatment or
other CHF therapy during the study period
that could have contributed to the symptomatic
improvement. In contrast, even a tendency to
discontinuation or to reduction in existing
beta-blocker therapy could be observed after
4 months. The results of our study emphasize
that there was room for further symptomatic
improvement in these patients, despite beta-
blocker treatment in line with current
guidelines the dosage of which can be
considered to be optimized at study inclusion.
Interestingly, at baseline, patients with higher
HRs tend to be treated with considerably higher
mean doses of metoprolol, which was the most
widely used beta-blocking agent in this patient
cohort. There are other studies confirming that
HR reduction is not consistently related to beta-
blocker dose [16]. For example, Franke et al. [8]
analyzed 443 CHF patients with an LVEF B35%
and NYHA class II–IV. After careful up-titration
of beta-blocker treatment, 29% of patients
reached the recommended target dose and
69% at least half of it. Despite this optimized
beta-blockade in clinical practice, 53% of
patients remained on an HR C75 bpm [8].
There is now also growing evidence from
recent clinical studies [17, 18] and also meta-
analyses of beta-blocker studies [19, 20] that
treatment in CHF patients should not be strictly
focused on achieving certain beta-blocker target
dosages, which seem not to be related to clinical
outcomes, but rather should concentrate on the
cumulative HR reduction that can be achieved
by different rate-reducing agents in the
therapeutic regimen. The magnitude of HR
reduction was closely correlated with
prognosis in the abovementioned studies.
HR reduction by ivabradine also improved
QOL considerably in the INTENSIFY study, as
reflected by the observed increase in EQ-5D
parameters. This finding is also in line with a
secondary analysis from the SHIFT trial,
showing that HR reduction by ivabradine
was associated with a significant increase in
QOL [21]. There was clear relationship
between the magnitude of HR reduction and
improvement in QOL, and also an inverse
relation between QOL measures and incidence
of the primary composite end point of the
trial. The QOL improvement in our study is of
considerable clinical relevance. The result lies
well within the range that can be achieved by
percutaneous coronary intervention treatment
in symptomatic patients with coronary artery
disease (roughly 0.2 index points on the EQ-
5D), which is an established treatment of
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proven efficacy in these patients [22].
Ivabradine produced similar improvements in
a large patient cohort with symptomatic
coronary artery disease in clinical practice
[23].
For CHF patients on the other hand, an
extensive meta-analysis failed to show a
significant improvement in QOL for beta-
blocker treatment, irrespective of proven
mortality reduction [24]. These results are
supported by a study by Riccioni et al. [25]
and also a head-to-head comparison trial of
ivabradine, carvedilol, or combination
treatment [15], demonstrating greater
improvement in QOL with ivabradine alone or
with combination therapy with carvedilol
compared with carvedilol alone. In this head-
to-head study, Volterrani et al. [15] found no
significant effect of carvedilol monotherapy on
QOL after 3 months of treatment versus
baseline. The positive effect of ivabradine on
QOL of CHF patients also needs to be
considered in the context that such data is, to
our knowledge, largely missing for other heart
failure standard medications (ACE inhibitors,
beta-blockers, mineralocorticoid receptor
antagonists). No improvement in QOL could
be demonstrated for beta-blockers, and only
modest effects or delay of progressive worsening
of QOL for ACE inhibitors [26]. No effect on
symptom status or QOL measures was seen in a
randomized trial with eplerenone compared
with placebo in NYHA II/III CHF patients [27].
Keeping in mind the growing relevance of QOL
improvement as an important therapeutic goal
in heart failure therapy, ivabradine seems to
provide a specific additional benefit here
compared with other prognostic standard
medications.
Taken together, the results from INTENSIFY
add to this evidence in demonstrating
additional improvement in symptoms and in
QOL in combination with standard beta-blocker
therapy.
STUDY LIMITATIONS
An important limitation of this trial is its open-
label, observational, non-interventional design
with no placebo group, which may lead to an
overestimation of the treatment effects. On the
other hand, the efficacy of ivabradine in
combination with beta-blocker has been
consistently proven in a large randomized
clinical trial with CHF patients [12]. Moreover,
the open study design allows evaluation of
treatment effects under conditions of routine
clinical practice, while in controlled studies
strict inclusion criteria usually restrict access of
broader patient populations with, for example,
multiple comorbidities and risk factors.
Another limitation is the relatively short
study duration of 4 months, which is
nevertheless sufficient to evaluate symptom
reduction and QOL in CHF patients, as already
demonstrated in other studies [14, 15, 24]. The
high resting HR at baseline can also lead to an
overestimation of the treatment benefit, as the
ivabradine effects are more pronounced in
patients with a high HR, due to its use-
dependent mechanism of action. But with
only slightly more than half of the patients
being up-titrated to the recommended
maintenance dose of ivabradine, treatment
effects may also be underestimated.
Due to the non-interventional design, an
underestimation of adverse events cannot be
fully excluded, as they were not specifically
looked for and were evaluated only in the form
of an open interview at each visit. But taking
into account favorable safety results from
controlled clinical trials, ivabradine in
combination with beta-blockers and other
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frequently prescribed drugs appears to be well
tolerated in CHF patients [12, 15].
CONCLUSION
In this prospective open-label study, ivabradine
was effective in reducing HR and symptoms in
CHF patients over a period of 4 months. There
was a marked reduction in the proportion of
patients showing signs of decompensation and
a LVEF B35% from baseline to study end. A shift
from higher to lower NYHA classes could also be
demonstrated. Furthermore, ivabradine reduced
BNP levels and improved QOL in this large
patient cohort. These benefits were
accompanied by good general tolerability. The
results of our study emphasize that there is still
potential for further symptom reduction and
corresponding QOL improvement in CHF
patients, despite optimized beta-blocker
treatment in line with current guideline
recommendations.
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